Veterinary Active Pharmaceutical Ingredients Manufacturing Market Report 2025

The veterinary active pharmaceutical ingredients manufacturing market size has grown strongly in recent years. It will grow from $7.46 billion in 2024 to $8.05 billion in 2025 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to rising pet ownership, stringent regulatory standards, increased focus on animal nutrition, research and development investments, global economic growth.

The veterinary active pharmaceutical ingredients manufacturing market size is expected to see strong growth in the next few years. It will grow to $11.19 billion in 2029 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to advancements in personalized veterinary medicine, globalization and market expansion, focus on regulatory compliance, growing importance of animal welfare, advancements in drug delivery systems, rising demand for nutraceuticals. Major trends in the forecast period include technological advancements in manufacturing processes, increasing outsourcing of API manufacturing, shift toward biotechnology-based APIs, digitalization and automation in manufacturing, globalization of the veterinary API market.

The rising number of pet owners is anticipated to drive the growth of the veterinary active pharmaceutical ingredients manufacturing market in the future. Pet owners are individuals who own or adopt pet animals and provide essential health services for them, thereby increasing the demand for veterinary drugs. For example, in 2022, Animal Medicines Australia, a non-governmental organization based in Australia, reported significant growth in pet ownership, with the number of pet owners reaching 28,730.8 in 2022, up from 39% in 2021. This marks a 24% increase, reflecting a strong upward trend in pet adoption and investment in care. The surge in pet ownership highlights the increasing popularity of pets in Australian households. Consequently, the growing number of pet owners is fueling the veterinary active pharmaceutical ingredients manufacturing market.

The increasing prevalence of zoonotic diseases is expected to boost the growth of the veterinary active pharmaceutical ingredients manufacturing market moving forward. A zoonotic disease, or zoonosis, is an infectious disease that can be naturally transmitted between animals and humans. Veterinary APIs are utilized in the development of vaccines that prevent the transmission of zoonotic diseases from animals to humans. Additionally, the use of veterinary APIs can help mitigate antibiotic resistance, which is a significant concern in treating zoonotic diseases. For instance, in February 2023, the Council on Foreign Relations (CFR), a U.S.-based independent, nonpartisan organization and think tank, reported that up to 75% of newly discovered or emerging infectious diseases (EIDs) and 60% of recognized infectious diseases have zoonotic origins. Zoonoses are responsible for 2.7 million human deaths and 2.5 billion cases of disease globally each year. Therefore, the increasing prevalence of zoonotic diseases is driving the growth of the veterinary active pharmaceutical ingredients manufacturing market.

Product innovation is a significant trend gaining traction in the veterinary active pharmaceutical ingredient manufacturing market. Key players in the industry are concentrating on developing innovative products to maintain their market positions. For example, in January 2022, Zoetis Inc., a U.S.-based company specializing in drugs for pets and livestock, announced the U.S. FDA approval of Solensia (frunevetmab injection) for managing osteoarthritis (OA) pain in cats. Solensia is the first injectable monoclonal antibody treatment for feline OA pain approved in the United States, functioning by targeting and neutralizing nerve growth factor (NGF), a primary contributor to pain in osteoarthritis.

Leading companies in the veterinary active pharmaceutical ingredient manufacturing market are focused on establishing manufacturing plants for APIs to gain a competitive advantage. These facilities produce active pharmaceutical ingredients used in veterinary drug formulations. For instance, in October 2023, Stallen South Asia Private Limited, an India-based animal health company, launched and commenced operations at a new veterinary API facility for Halquinol, a non-antibiotic growth promoter from the hydroxyquinoline group. This product is a combination of 5-chloro-8-hydroxyquinoline, 5,7-dichloro-8-hydroxyquinoline, and 7-chloro-8-hydroxyquinoline. The facility produces Halquinol 98%, manufactured in accordance with British Pharmacopeia 1980 (BP 80) guidelines. Alongside the more common 60% and 12% formulations, Stallen can also offer 98% as a chemical API used in veterinary formulations and feed additives. Stallen aims to reduce the dependence on products sourced from China for the animal health industry by gradually introducing a diverse range of APIs from this facility.

In June 2022, Orion Corporation, a Finland-based company in the human and veterinary pharmaceutical industry, acquired Inovet (V.M.D. nv/sa) for $128.33 million (130 million euros). This acquisition will allow Orion's Veterinary Medicines division to expand its product portfolio and establish a presence in the production animal market, as well as increase its geographical reach in Western Europe and the export market. Inovet (V.M.D. nv/sa) is a Belgium-based manufacturer of veterinary active pharmaceutical ingredients.

Major companies operating in the veterinary active pharmaceutical ingredients manufacturing market are Alivira Animal Health Limited, Excel Industries Limited, Ofichem Group B.V., Jiangsu Lingyun Pharmaceutical Co. Ltd., SUANFARMA S.A., NGL Fine-Chem Limited, FIS - Fabbrica Italiana Sintetici S.p.A., Lupin Limited, Aurobindo Pharma Limited, Saneca Pharmaceuticals AS, Neuland Laboratories Limited, Divi's Laboratories Limited, Zoetis Inc., Grupo Indukern S.L., Sequent Scientific Limited, Chempro Pharma Private Limited, AMGIS Lifescience Ltd., Huvepharma AD, Vetpharma Animal Health S.L., Qilu Pharma Spain S.A., INDUKERN Chemie AG, Chemopharma S.A., Norbrook Laboratories Limited, Ceva Santé Animale S.A., Vetoquinol S.A., Virbac S.A.

North America was the largest region in the veterinary active pharmaceutical ingredients manufacturing market in 2024. The regions covered in the veterinary active pharmaceutical ingredients manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the veterinary active pharmaceutical ingredients manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Veterinary Active Pharmaceutical Ingredients (APIs) manufacturing involves the production of chemical compounds that are biologically active and utilized in the formulation of veterinary medicines. These APIs play a crucial role in treating diseases and maintaining health in animals, including both livestock and pets. The manufacturing process is designed to ensure the quality, safety, and efficacy of the medications that enhance animal welfare and health outcomes.

The primary products within veterinary active pharmaceutical ingredients manufacturing encompass anti-infectives, vaccines, and NSAIDs. Active Pharmaceutical Ingredients (APIs) are the core elements of pharmaceutical medications that exert specific effects on the body, aiding in the treatment of diseases. Service types associated with this field include in-house production and contract outsourcing. Additionally, synthetic types of APIs comprise chemical-based APIs, biological APIs, and highly potent APIs. These categories delineate the diverse methodologies involved in producing these vital components for veterinary pharmaceuticals.

The veterinary active pharmaceutical ingredients manufacturing market research report is one of a series of new reports that provides veterinary active pharmaceutical ingredients manufacturing market statistics, including veterinary active pharmaceutical ingredients manufacturing industry global market size, regional shares, competitors with veterinary active pharmaceutical ingredients manufacturing market share, detailed veterinary active pharmaceutical ingredients manufacturing market segments, market trends and opportunities, and any further data you may need to thrive in the veterinary active pharmaceutical ingredients manufacturing industry. This veterinary active pharmaceutical ingredient manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The veterinary active pharmaceutical ingredients manufacturing market consists of revenues earned by entities by biologics and bulk drugs that are used to create components in medications which are responsible for the positive veterinary health impacts. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.